Zentalis Pharmaceuticals, Inc.
ZNTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001725160
In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Zentalis Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 134 | 1 | 137 | +4 |
| Shares | 82.5M | 40.2K | 80.2M | −2.22M (−2.7%) |
| Value | $2.32B | $1.13M | $1.61B | −$713.7M (−30.7%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Zentalis Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Qube Research & Technologies Ltd | 141,388 | $2.84M | 0.01% |
| Twinbeech Capital LP | 128,859 | $2.58M | 0.05% |
| D. E. Shaw & Co., Inc. | 37,439 | $751.0K | 0.00% |
| Tudor Investment Corp Et Al | 35,225 | $706.6K | 0.01% |
| Gsa Capital Partners LLP | 24,344 | $488.0K | 0.04% |
| Engineers Gate Manager LP | 22,611 | $453.6K | 0.02% |
| XTX Topco Ltd | 19,008 | $381.3K | 0.07% |
| Virtu Financial LLC | 16,223 | $325.0K | 0.03% |
| Regency Capital Management Inc. | 15,000 | $300.9K | 0.26% |
| Schonfeld Strategic Advisors LLC | 14,900 | $298.9K | 0.00% |
| Graham Capital Management, L.P. | 10,600 | $212.6K | 0.01% |
| GTS Securities LLC | 9,987 | $200.3K | 0.00% |
| Simplex Trading, LLC | 2,213 | $44.0K | 0.00% |
| KBC Group NV | 904 | $18.0K | 0.00% |
| Cutler Group LP | 900 | $18.0K | 0.00% |
| Comerica Bank | 143 | $2.87K | 0.00% |
| FinTrust Capital Advisors, LLC | 17 | $335 | 0.00% |
Sold out (13)
Institutions that held Zentalis Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Deep Track Capital, LP | 300,300 | $8.47M |
| EcoR1 Capital, LLC | 300,000 | $8.46M |
| Jefferies Financial Group Inc. | 93,900 | $2.65M |
| Jump Financial, LLC | 31,570 | $890.6K |
| Skandinaviska Enskilda Banken AB (publ) | 22,800 | $643.0K |
| ExodusPoint Capital Management, LP | 18,410 | $519.0K |
| NinePointTwo Capital | 10,716 | $302.0K |
| Bridgefront Capital, LLC | 10,560 | $297.9K |
| Handelsbanken Fonder AB | 8,300 | $234.0K |
| Bayesian Capital Management, LP | 8,011 | $226.0K |
| Fox Run Management, L.L.C. | 7,760 | $218.9K |
| Scharf Investments, LLC | 7,531 | $212.4K |
| Ronald Blue Trust, Inc. | 7 | $0 |
Not filed for Q3 2023 yet (1)
Institutions that held Zentalis Pharmaceuticals, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 40,156 | $1.13M |